The drug ublituximab beat a standard oral medication for MS in reducing patients' relapses and proved better at preventing areas of inflammatory damage in the brain.
https://ift.tt/euBbNkS
from WebMD Health https://ift.tt/NX3Rw1G
by
The drug ublituximab beat a standard oral medication for MS in reducing patients' relapses and proved better at preventing areas of inflammatory damage in the brain.
Comments
Post a Comment